While ZOL did not significantly upregulate NKG2D ligands or decrease OS cell viability directly, its ability to condition tumor cells for γδ TCR-dependent killing underscores the importance of antigen-specific recognition in mediating therapeutic efficacy. This evidence concerns the gene KLRK1 and neoplasm.